Annovis Bio Management
Management criteria checks 2/4
Annovis Bio's CEO is Maria Maccecchini, appointed in May 2008, has a tenure of 16.5 years. total yearly compensation is $2.15M, comprised of 31.1% salary and 68.9% bonuses, including company stock and options. directly owns 7.96% of the company’s shares, worth $7.30M. The average tenure of the management team and the board of directors is 1.3 years and 8.8 years respectively.
Key information
Maria Maccecchini
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 31.1% |
| CEO tenure | 16.5yrs |
| CEO ownership | 8.0% |
| Management average tenure | 1.3yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
Annovis Bio To Continue Alzheimer's Disease Clinical Trials
Oct 17Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom
Sep 27Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints
Jul 08Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Jun 30Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08
Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?
Feb 23We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth
Jan 01
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$43m |
| Mar 31 2024 | n/a | n/a | -US$48m |
| Dec 31 2023 | US$2m | US$668k | -US$56m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$3m | US$636k | -US$25m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$9m | US$510k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$8m |
| Dec 31 2020 | US$1m | US$420k | -US$5m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$3m |
| Mar 31 2020 | n/a | n/a | -US$1m |
| Dec 31 2019 | US$120k | US$120k | -US$991k |
| Sep 30 2019 | n/a | n/a | -US$958k |
| Jun 30 2019 | n/a | n/a | -US$841k |
| Mar 31 2019 | n/a | n/a | -US$715k |
| Dec 31 2018 | US$155k | US$120k | -US$714k |
Compensation vs Market: Maria's total compensation ($USD2.15M) is above average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Maria's compensation has been consistent with company performance over the past year.
CEO
Maria Maccecchini (73 yo)
16.5yrs
Tenure
US$2,145,852
Compensation
Dr. Maria L. Maccecchini, Ph D., serves as Independent Director of Lantern Pharma Inc. from June 08, 2022. She is the Founder of Annovis Bio, Inc. and has been its Chief Executive Officer and President sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.5yrs | US$2.15m | 7.96% $ 7.3m | |
| Chief Business Officer & Director | less than a year | US$135.43k | 0.44% $ 406.8k | |
| Senior Vice President of Research & Development | 2.8yrs | no data | no data | |
| Senior Vice President of Regulatory Operations | 2.8yrs | no data | no data | |
| Senior Vice President of Clinical Operations | 1.3yrs | no data | no data | |
| Head of Quality | less than a year | no data | no data | |
| Senior Vice President of Statistics | less than a year | no data | no data |
1.3yrs
Average Tenure
Experienced Management: ANVS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.5yrs | US$2.15m | 7.96% $ 7.3m | |
| Chief Business Officer & Director | 8.8yrs | US$135.43k | 0.44% $ 406.8k | |
| Independent Chairman of the Board | 10.8yrs | US$153.92k | 11.88% $ 10.9m | |
| Chief Medical Advisor & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Independent Director | 3.6yrs | US$143.92k | 0.053% $ 48.6k | |
| Chairman of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Independent Director | 9.8yrs | US$135.43k | 0.048% $ 43.7k |
8.8yrs
Average Tenure
71.5yo
Average Age
Experienced Board: ANVS's board of directors are considered experienced (8.8 years average tenure).